BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 30805301)

  • 1. "Energetic" Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy.
    Fiorillo M; Sotgia F; Lisanti MP
    Front Oncol; 2018; 8():677. PubMed ID: 30805301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.
    Ozsvari B; Bonuccelli G; Sanchez-Alvarez R; Foster R; Sotgia F; Lisanti MP
    Aging (Albany NY); 2017 Dec; 9(12):2610-2628. PubMed ID: 29253841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
    Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MitoTracker Deep Red (MTDR) Is a Metabolic Inhibitor for Targeting Mitochondria and Eradicating Cancer Stem Cells (CSCs), With Anti-Tumor and Anti-Metastatic Activity
    Sargiacomo C; Stonehouse S; Moftakhar Z; Sotgia F; Lisanti MP
    Front Oncol; 2021; 11():678343. PubMed ID: 34395247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells.
    De Luca A; Fiorillo M; Peiris-Pagès M; Ozsvari B; Smith DL; Sanchez-Alvarez R; Martinez-Outschoorn UE; Cappello AR; Pezzi V; Lisanti MP; Sotgia F
    Oncotarget; 2015 Jun; 6(17):14777-95. PubMed ID: 26087310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways.
    Bonuccelli G; Sotgia F; Lisanti MP
    Aging (Albany NY); 2018 Aug; 10(8):1867-1883. PubMed ID: 30153655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity.
    Sánchez-Alvarez R; De Francesco EM; Fiorillo M; Sotgia F; Lisanti MP
    Front Oncol; 2020; 10():1776. PubMed ID: 33194575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NADH autofluorescence, a new metabolic biomarker for cancer stem cells: Identification of Vitamin C and CAPE as natural products targeting "stemness".
    Bonuccelli G; De Francesco EM; de Boer R; Tanowitz HB; Lisanti MP
    Oncotarget; 2017 Mar; 8(13):20667-20678. PubMed ID: 28223550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.
    Fiorillo M; Lamb R; Tanowitz HB; Mutti L; Krstic-Demonacos M; Cappello AR; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Oncotarget; 2016 Jun; 7(23):34084-99. PubMed ID: 27136895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant.
    Farnie G; Sotgia F; Lisanti MP
    Oncotarget; 2015 Oct; 6(31):30472-86. PubMed ID: 26421710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis.
    Ozsvari B; Sotgia F; Lisanti MP
    Aging (Albany NY); 2017 Oct; 9(10):2098-2116. PubMed ID: 29080556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells.
    Lamb R; Ozsvari B; Bonuccelli G; Smith DL; Pestell RG; Martinez-Outschoorn UE; Clarke RB; Sotgia F; Lisanti MP
    Oncotarget; 2015 Sep; 6(26):21892-905. PubMed ID: 26323205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling.
    Lamb R; Bonuccelli G; Ozsvári B; Peiris-Pagès M; Fiorillo M; Smith DL; Bevilacqua G; Mazzanti CM; McDonnell LA; Naccarato AG; Chiu M; Wynne L; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Oncotarget; 2015 Oct; 6(31):30453-71. PubMed ID: 26421711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine).
    De Francesco EM; Ózsvári B; Sotgia F; Lisanti MP
    Front Oncol; 2019; 9():615. PubMed ID: 31440463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity.
    Ózsvári B; Magalhães LG; Latimer J; Kangasmetsa J; Sotgia F; Lisanti MP
    Front Oncol; 2020; 10():1528. PubMed ID: 33042796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallmarks of the cancer cell of origin: Comparisons with "energetic" cancer stem cells (e-CSCs).
    Sotgia F; Fiorillo M; Lisanti MP
    Aging (Albany NY); 2019 Feb; 11(3):1065-1068. PubMed ID: 30760648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy.
    De Francesco EM; Maggiolini M; Tanowitz HB; Sotgia F; Lisanti MP
    Oncotarget; 2017 Aug; 8(34):56126-56142. PubMed ID: 28915578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs).
    Fiorillo M; Tóth F; Sotgia F; Lisanti MP
    Aging (Albany NY); 2019 Apr; 11(8):2202-2216. PubMed ID: 31002656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX.
    Sotgia F; Ozsvari B; Fiorillo M; De Francesco EM; Bonuccelli G; Lisanti MP
    Cell Cycle; 2018; 17(17):2091-2100. PubMed ID: 30257595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.
    Lamb R; Harrison H; Hulit J; Smith DL; Lisanti MP; Sotgia F
    Oncotarget; 2014 Nov; 5(22):11029-37. PubMed ID: 25415228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.